No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
FHTX Foghorn Therapeutics
- 5.630
- -0.200-3.43%
Close May 7 16:00 ET
239.76MMarket Cap-2559P/E (TTM)
6.034High5.620Low58.27KVolume5.830Open5.830Pre Close338.90KTurnover0.27%Turnover RatioLossP/E (Static)42.59MShares9.97052wk High-2.46P/B120.29MFloat Cap2.70052wk Low--Dividend TTM21.37MShs Float28.265Historical High--Div YieldTTM7.11%Amplitude2.700Historical Low5.816Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Foghorn Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Foghorn Therapeutics (FHTX.US): The 2024 Q1 financial report achieved revenue of US$5.05 million, with a previous value of US$5.39 million and an expected value of US$6.91 million; earnings per share were -0.59 dollars, previous value was -0.73 dollars, a
Foghorn Therapeutics (FHTX.US): The 2024 Q1 financial report achieved revenue of US$5.05 million, with a previous value of US$5.39 million and an expected value of US$6.91 million; earnings per share were -0.59 dollars, previous value was -0.73 dollars, and expected value was -0.63 dollars.
Foghorn Therapeutics Q1 2024 Earnings: Misses Analyst Revenue Projections Amidst Strategic ...
Foghorn Therapeutics | 10-Q: Quarterly report
Foghorn Therapeutics 1Q Loss $25M >FHTX
Foghorn Therapeutics 1Q Loss $25M >FHTX
Foghorn Therapeutics 1Q Loss/Shr 59c >FHTX
Foghorn Therapeutics 1Q Loss/Shr 59c >FHTX
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg